As of November 6, 2026, Lucid Diagnostics Inc. is a publicly traded company (Nasdaq: LUCD). The largest holder reporting an active stake on Schedule 13D is PAVmed Inc., at 27.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, February 9, 2026).
Is this your company?
About to sign with, pay or invest in Lucid Diagnostics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Lucid Diagnostics Inc. a real, registered company?
- Lucid Diagnostics Inc. files with the SEC under CIK 1799011 (its SEC filings).
- Its shares are listed under the ticker LUCD on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Lucid Diagnostics Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names PAVmed Inc. (filed 2026-02-09).
Who are Lucid Diagnostics Inc.'s owners and officers?
Lucid Diagnostics Inc.: incorporated in Delaware; business address in New York, New York; industry Surgical & Medical Instruments & Apparatus (Schedule 13D/A, 2026-02-09).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2024-12-06)
- : Executive Officer (Form D, 2024-12-06)
- : Executive Officer (Form D, 2024-12-06)
- : Executive Officer (Form D, 2024-12-06)
- : Director (Form D, 2024-12-06)
- : Director (Form D, 2024-12-06)
- : Director (Form D, 2024-12-06)
- : Director (Form D, 2024-12-06)
- : Director (Form D, 2024-12-06)
- : Director (Form D, 2024-12-06)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-02-09 | Pavmed Inc. | 27.5% |
| Schedule 13D/A, 2025-10-10 | Pavmed Inc. | 28.3% |
Questions about who owns Lucid Diagnostics Inc.
Who owns Lucid Diagnostics Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Lucid Diagnostics Inc.: Pavmed Inc. (27.5%, Schedule 13D/A, filed 2026-02-09).
When did Pavmed Inc. buy into Lucid Diagnostics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Pavmed Inc. on this page is the Schedule 13D/A, filed 2025-10-10, reporting 28.3%; its latest, Schedule 13D/A filed 2026-02-09, reports 27.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Lucid Diagnostics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lucid Diagnostics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lucid Diagnostics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Lucid Diagnostics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 3,636,627 shares (1.8% of shares outstanding) (Form 4, 2026-02-24).
- , the chief financial officer: 1,813,569 shares (0.89% of shares outstanding) (Form 4, 2026-02-24).
- , the president and chief operating officer: 1,446,763 shares (0.71% of shares outstanding) (Form 4, 2026-02-24).
- , a director: 1,033,443 shares (0.51% of shares outstanding) (Form 4, 2026-05-21).
- , the general counsel and secretary: 1,000,000 shares (0.49% of shares outstanding) (Form 4, 2026-02-24).
Shares outstanding: 203,243,970 as of 2026-08-10, from the company's latest SEC cover page.
How much has Lucid Diagnostics Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2024-12-06 | $21.95M | $21.95M |
| Form D, 2023-11-01 | $5M | $5M |
| Form D, 2023-04-05 | $11.11M | $11.11M |
| Form D, 2023-03-22 | $13.63M | $20M |
Keep reading
More on Lucid Diagnostics Inc. and the records around it.
The people at Lucid Diagnostics Inc.
- DENNIS MCGRATH is also named on 6 other Form D filings: PAVmed Inc. (Feb 2026), DarioHealth Corp. (Oct 2025), Veris Health Inc. (Jul 2025)
- DENNIS MATHEIS is also named on 3 other Form D filings: DarioHealth Corp. (Oct 2025)
- LISHAN AKLOG is also named on 3 other Form D filings: PAVmed Inc. (Feb 2026), Veris Health Inc. (Jul 2025)
- DEBRA WHITE, MICHAEL GORDON, RONALD SPARKS and SHAUN O'NEIL are also named on 2 other Form D filings: PAVmed Inc. (Feb 2026)
Lucid Diagnostics Inc. elsewhere on the record
- 5%+ stake filings Feb 2026
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/lucid-diagnostics